Ending tuberculosis by 2030: can we do it?
- PMID: 27510238
- DOI: 10.5588/ijtld.16.0142
Ending tuberculosis by 2030: can we do it?
Abstract
The Sustainable Development Goals aim to end tuberculosis (TB) related deaths, transmission and catastrophic costs by 2030. Multisectorial action to accelerate socio-economic development, a new vaccine and novel diagnostics and medicines for treatment are key advances needed to end TB transmission. Achieving 90-90-90 targets for TB (i.e., 90% of vulnerable populations screened, 90% diagnosed and started on treatment, and at least 90% cured) will help accelerate progress towards reductions in mortality; however, passive case detection strategies, multidrug-resistant TB, human immunodeficiency virus coinfection and outdated pathways to care need to be overcome. Ending the catastrophic costs associated with TB will require expansion of health insurance coverage, comprehensive coverage of TB services, and limited indirect costs by vulnerable and poor populations.
Similar articles
-
Cost effectiveness of decentralised care model for managing MDR-TB in India.Indian J Tuberc. 2018 Jul;65(3):208-217. doi: 10.1016/j.ijtb.2017.08.031. Epub 2017 Sep 28. Indian J Tuberc. 2018. PMID: 29933862
-
Cost-effectiveness of treating multidrug-resistant tuberculosis.PLoS Med. 2006 Jul;3(7):e241. doi: 10.1371/journal.pmed.0030241. PLoS Med. 2006. PMID: 16796403 Free PMC article.
-
Cost of multi drug resistance tuberculosis in Germany.Respir Med. 2014 Nov;108(11):1677-87. doi: 10.1016/j.rmed.2014.09.021. Epub 2014 Oct 15. Respir Med. 2014. PMID: 25443398
-
Drug-resistant TB: deadly, costly and in need of a vaccine.Trans R Soc Trop Med Hyg. 2016 Mar;110(3):186-91. doi: 10.1093/trstmh/trw006. Trans R Soc Trop Med Hyg. 2016. PMID: 26884499 Free PMC article. Review.
-
The re-emergence of tuberculosis.Annu Rev Public Health. 1994;15:303-23. doi: 10.1146/annurev.pu.15.050194.001511. Annu Rev Public Health. 1994. PMID: 8054087 Review.
Cited by
-
Impact of the improvement of living conditions on tuberculosis mortality in Brazil: an ecological study.Sao Paulo Med J. 2024 Aug 26;142(6):e2023279. doi: 10.1590/1516-3180.2023.0279.R1.13052024. eCollection 2024. Sao Paulo Med J. 2024. PMID: 39194067 Free PMC article.
-
Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.PLoS Med. 2017 Jan 3;14(1):e1002202. doi: 10.1371/journal.pmed.1002202. eCollection 2017 Jan. PLoS Med. 2017. PMID: 28045934 Free PMC article.
-
A New Financing Model for Tuberculosis (TB) Care in China: Challenges of Policy Development and Lessons Learned from the Implementation.Int J Environ Res Public Health. 2020 Feb 21;17(4):1400. doi: 10.3390/ijerph17041400. Int J Environ Res Public Health. 2020. PMID: 32098125 Free PMC article. Review.
-
Evaluating systematic targeted universal testing for tuberculosis in primary care clinics of South Africa: A cluster-randomized trial (The TUTT Trial).PLoS Med. 2023 May 22;20(5):e1004237. doi: 10.1371/journal.pmed.1004237. eCollection 2023 May. PLoS Med. 2023. PMID: 37216385 Free PMC article. Clinical Trial.
-
Assessing the impacts of short-course multidrug-resistant tuberculosis treatment in the Southeast Asia Region using a mathematical modeling approach.PLoS One. 2021 Mar 26;16(3):e0248846. doi: 10.1371/journal.pone.0248846. eCollection 2021. PLoS One. 2021. PMID: 33770104 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources